Buy Generic Hydroxyurea Online

Generic Hydroxyurea Information

Introduction

Hydroxyurea is an oral antimetabolite that belongs to the cancer‑therapy drug group. It is used primarily to control abnormal cell proliferation in several hematologic and oncologic conditions. In Hong Kong, Hydroxyurea is listed on the Hospital Authority formulary for specific indications such as chronic myeloid leukaemia (CML) in the chronic phase, sickle‑cell disease, and certain solid tumours. The medication is manufactured by several global pharmaceutical firms; the active compound is Hydroxyurea itself. In addition to its oncologic role, Hydroxyurea is recognised for reducing vaso‑occlusive crises in sickle‑cell disease and for managing severe thrombocytosis when other therapies are unsuitable.

What is Hydroxyurea?

Hydroxyurea is a synthetic, low‑molecular‑weight compound (C₂H₅N₃O₂) that inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis. It was first approved by the United States Food and Drug Administration (FDA) in 1967 for chronic myeloid leukaemia and later expanded to other indications. Commercially, the drug is available under several brand names, the most widely recognised being Hydrea (produced by Bristol‑Myers Squibb).

Hydroxyurea is the generic version of Hydrea, containing the same active compound Hydroxyurea. Our online pharmacy provides this generic alternative as a cost‑effective treatment option, offering the same therapeutic benefits at near‑manufacturer pricing for patients in Hong Kong.

How Hydroxyurea Works

Hydroxyurea exerts its therapeutic effect by irreversibly inhibiting ribonucleotide reductase, the enzyme that converts ribonucleotides to deoxyribonucleotides, the building blocks of DNA. By depleting the intracellular pool of deoxyribonucleic acid precursors, the drug halts DNA replication in rapidly dividing cells, leading to cell‑cycle arrest in the S phase.

In sickle‑cell disease, Hydroxyurea increases the production of fetal hemoglobin (HbF) through a separate mechanism that involves nitric‑oxide donation and modulation of gene expression. Higher HbF levels reduce the polymerisation of sickle hemoglobin (HbS), decreasing red‑cell rigidity and the frequency of vaso‑occlusive events.

Pharmacokinetic data show that Hydroxyurea is rapidly absorbed after oral administration, achieving peak plasma concentrations within 1–2 hours. It is metabolised mainly by non‑enzymatic oxidation and excreted unchanged in the urine; the elimination half‑life ranges from 2 to 4 hours in individuals with normal renal function. These properties explain the need for daily dosing to maintain therapeutic steady‑state levels.

Conditions Treated with Hydroxyurea

• Chronic Myeloid Leukaemia (CML) – chronic phase
  Hydroxyurea reduces leukocyte counts and controls disease progression when tyrosine‑kinase inhibitors are contraindicated or unavailable.

• Sickle‑Cell Disease
  By raising HbF, Hydroxyurea lowers the incidence of painful crises, acute chest syndrome, and the need for blood transfusion.

• Polycythemia Vera and Essential Thrombocythemia
  The drug suppresses bone‑marrow proliferation, decreasing hematocrit and platelet counts when phlebotomy or interferon therapy is unsuitable.

• Certain Solid Tumours (e.g., head and neck, melanoma)
  Hydroxyurea may be employed as part of combination chemotherapy regimens, exploiting its antiproliferative effect on tumour cells.

• Human Immunodeficiency Virus (HIV) – investigational
  Early studies indicated a modest reduction in viral replication; however, it is not a standard therapy.

In Hong Kong, the prevalence of sickle‑cell disease is low but rising due to migration from regions where the condition is endemic. The Hospital Authority reports several hundred patients undergoing Hydroxyurea therapy for sickle‑cell disease, underscoring the drug’s clinical relevance locally.

Suitable Candidates for Hydroxyurea Treatment

Hydroxyurea is appropriate for adult patients who meet any of the following criteria:

• Confirmed diagnosis of chronic‑phase CML where first‑line tyrosine‑kinase inhibitors are contraindicated, not tolerated, or unavailable.
• Sickle‑cell disease with ≥3 vaso‑occlusive crises per year, or a documented need to reduce transfusion frequency.
• Myeloproliferative neoplasms (polycythemia vera or essential thrombocythemia) with persistent high blood counts despite optimal phlebotomy or cytoreductive therapy.
• Solid‑tumour protocols where Hydroxyurea is listed as an adjunct cytotoxic agent, typically in combination with other chemotherapeutics.

Patients should undergo baseline laboratory evaluation—including complete blood count, renal and hepatic panels, and pregnancy testing for women of child‑bearing potential—before initiating therapy.

Contra‑indications include:

• Known hypersensitivity to Hydroxyurea or any excipient.
• Pregnancy or breastfeeding, due to teratogenic risk.
• Severe renal impairment (creatinine clearance <30 mL/min) unless dose‑adjusted under specialist supervision.
• Pre‑existing severe bone‑marrow suppression (e.g., absolute neutrophil count <1. × 10⁹/L, platelet count <50 × 10⁹/L).

Patients with a history of hypersensitivity to other antimetabolites, or those taking strong cytotoxic agents concurrently, require careful risk‑benefit assessment.

Risks, Side Effects, and Interactions

Common

• Myelosuppression – mild neutropenia, thrombocytopenia, or anemia.
• Gastrointestinal upset – nausea, vomiting, anorexia, or diarrhoea.
• Dermatologic reactions – skin hyperpigmentation, rash, or mild alopecia.
• Mouth ulcers – painless or mildly painful lesions on the oral mucosa.

These events are often dose‑related and reversible upon dose reduction or temporary discontinuation.

Rare

• Macrocytosis – enlargement of red blood cells without significant anemia.
• Renal dysfunction – modest rise in serum creatinine, usually reversible.
• Elevated liver enzymes – transient transaminitis, particularly in patients with pre‑existing hepatic disease.

Monitoring of renal and hepatic function at baseline and every 2–3 months is advised.

Serious

• Severe bone‑marrow suppression – pancytopenia leading to infection or bleeding risk. Immediate medical evaluation required.
• Cutaneous malignant transformation – rare cases of squamous cell carcinoma reported after long‑term exposure. Skin surveillance is recommended for patients on chronic therapy.
• Teratogenicity – congenital malformations reported when exposure occurs during the first trimester. Contraception must be used throughout treatment and for at least 3 months after cessation.

Drug–Drug Interactions

• Antiretroviral agents (e.g., zidovudine) – additive myelosuppression.
• Phenytoin, carbamazepine – potential reduction of Hydroxyurea plasma levels through increased clearance.
• Vaccines (live attenuated) – risk of uncontrolled infection; avoid during periods of profound leukopenia.

Patients should disclose all concurrent medications, including over‑the‑counter supplements, to their healthcare provider.

Practical Use: Dosing, Missed Dose, Overdose

Standard dosing ranges (adult, general guidance only):

• CML (chronic phase): 500 mg orally twice daily; dose may be escalated to 1 g twice daily based on leukocyte response and tolerability.
• Sickle‑cell disease: 15 mg/kg once daily, not to exceed 1 g per day; dose is titrated upward every 2–4 weeks to achieve maximal HbF increase while monitoring blood counts.
• Polycythemia vera / essential thrombocythemia: 500 mg–1 g orally once daily, adjusted according to haematocrit and platelet targets.

Exact dosing must be prescribed by a qualified clinician; the figures above serve only as an illustration of typical regimens.

Missed Dose

If a dose is missed and the scheduled time for the next dose is more than 6 hours away, take the missed dose. If less than 6 hours remain, skip the missed dose and resume the regular schedule. Do not double the dose to compensate.

Overdose

Signs of overdose include profound myelosuppression, severe nausea, vomiting, and dehydration. Immediate medical attention is essential. Management is supportive: intravenous fluids, anti‑emetics, and possible growthfactor support (e.g., filgrastim) for severe neutropenia. There is no specific antidote for Hydroxyurea toxicity.

Practical Precautions

• Food: Hydroxyurea may be taken with or without food; however, a light snack can reduce gastrointestinal irritation.
• Alcohol: Moderate alcohol intake is permissible, but excessive consumption may worsen liver enzyme elevations.
• Renal or hepatic impairment: Dose reduction (often 25–50 % of the standard dose) is recommended; close laboratory monitoring is mandatory.
• Contraception: Effective barrier or hormonal contraception must be used throughout treatment and for at least 3 months after the final dose.

Buying Hydroxyurea from Our Online Pharmacy

Hydroxyurea can be purchased from our online pharmacy in Hong Kong with a streamlined, confidential ordering process.

• Affordable pricing: We source the generic formulation directly from certified overseas manufacturers, allowing us to offer Hydroxyurea at near‑manufacturer cost, considerably lower than locally branded equivalents.
• Verified quality: Every batch is verified by third‑party laboratories for potency, purity, and compliance with international Good Manufacturing Practice (GMP) standards.
• Guaranteed delivery: Discreet packaging is dispatched via 7‑day express courier for Hong Kong residents, with a regular airmail option taking approximately 3 weeks for overseas orders.
• Online‑only access: Our pharmacy broker service collaborates with licensed overseas pharmacies, enabling patients who face limited local availability or restrictive insurance formularies to obtain Hydroxyurea safely.

Because Hydroxyurea is a prescription‑only medication in Hong Kong, we require a valid prescription from a licensed practitioner before dispatch. Our platform ensures privacy, regulatory compliance, and reliable supply for patients who need uninterrupted therapy.

FAQ

• Is Hydroxyurea available in both brand‑name and generic forms in Hong Kong?
  Yes. The original brand name is Hydrea, while generic Hydroxyurea contains the identical active ingredient. Generic versions are typically less expensive and are offered by our online pharmacy as a cost‑effective alternative.

• Does Hydroxyurea require cold storage?
  No. Hydroxyurea tablets should be stored at room temperature, away from direct sunlight, heat, and moisture. Refrigeration is unnecessary and may cause condensation that degrades the product.

• What packaging does Hydroxyurea come in when ordered online?
  The medication is supplied in sealed, tamper‑evident blister packs containing 30 tablets per strip. Each package includes a patient information leaflet in English and Chinese, and the outer box is wrapped in discreet, unbranded material for privacy.

• Can Hydroxyurea be safely imported into Hong Kong for personal use?
  Personal import of prescription medicines is permitted under Hong Kong customs regulations when a valid prescription is presented. Our online pharmacy assists customers in complying with these requirements, ensuring that all shipments meet local import standards.

• Are there manufacturer warnings specific to Asian populations?
  Clinical data indicate that Asian patients may experience similar efficacy and safety profiles to other ethnic groups. However, some studies suggest a slightly higher incidence of mild hepatic enzyme elevation, prompting closer liver function monitoring in this population.

• Does Hydroxyurea have formulation differences between regions (e.g., US vs EU vs Asia)?
  The active ingredient and dosage strength are consistent worldwide. In some regions, inactive excipients such as lactose or magnesium stearate may vary, which could affect patients with specific allergies. Our generic formulation uses hypoallergenic excipients approved for the Asian market.

• How does Hydroxyurea affect fertility in men and women?
  Hydroxyurea can cause reversible oligospermia in men and may impair ovarian function in women. Fertility assessments are recommended before initiating long‑term therapy, and effective contraception should be used throughout treatment.

• What is the typical time frame to see clinical improvement in sickle‑cell disease?
  Increases in fetal hemoglobin usually become measurable after 2–3 months of consistent dosing, with a corresponding reduction in vaso‑occlusive crises often evident by 4–6 months. Ongoing monitoring is essential to adjust dosing for optimal benefit.

• Is there a risk of developing resistance to Hydroxyurea in cancer treatment?
  Resistance can develop through up‑regulation of ribonucleotide reductase subunits or increased drug efflux. In clinical practice, resistance is monitored by serial blood counts and disease markers; combination regimens are frequently employed to mitigate this risk.

• Can Hydroxyurea be taken together with vitamins or herbal supplements?
  Most vitamins and minerals do not interfere with Hydroxyurea. However, antioxidants such as high‑dose vitamin C may theoretically reduce the drug’s oxidative stress‑mediated effects. Patients should discuss all supplements with their healthcare provider to avoid unforeseen interactions.

• What are the travel considerations for carrying Hydroxyurea abroad?
  Carry the medication in its original packaging with a copy of the prescription. Notify customs authorities if required, and keep the medication in carry‑on luggage to avoid temperature extremes that may occur in checked baggage.

Glossary

Ribonucleotide Reductase

An enzyme that converts ribonucleotides to deoxyribonucleotides, essential for DNA synthesis. Hydroxyurea blocks this enzyme, halting cell division.

Fetal Hemoglobin (HbF)

A form of hemoglobin produced in the fetus; its presence in adults reduces sickling of red cells in sickle‑cell disease. Hydroxyurea increases HbF levels.

Myelosuppression

Decreased production of blood cells in the bone marrow, leading to anemia, neutropenia, or thrombocytopenia. It is a common dose‑related side effect of many chemotherapeutic agents, including Hydroxyurea.Teratogenicity**

The capacity of a substance to cause birth defects. Hydroxyurea is classified as teratogenic and must be avoided during pregnancy.

⚠️ Disclaimer

The information provided about Hydroxyurea is for general knowledge only. It does not replace professional medical consultation. All treatment decisions should be made under the supervision of a qualified healthcare provider. We assume all readers are responsible adults capable of making informed decisions about their health. Our online pharmacy offers access to Hydroxyurea for individuals who may have limited availability through traditional pharmacies, prescription‑based insurance schemes, or who are seeking affordable generic alternatives. Always consult your doctor before starting, changing, or discontinuing any medication.